Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
A most cancers analysis can deliver massive modifications—emotionally, bodily, and financially. Between paying for remedy, managing a diminished revenue, and understanding insurance...
AUGUSTA, GA (October 7, 2025) LiveLung, a 501(c)(3) nonprofit group devoted to supporting lung most cancers sufferers, survivors, and their care companions,...
